HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya Leadership skills development workshop organized by Tanzania Global Learning Agency to @NIMRMbeya leadership team,… https://t.co/CHUsREcpwi
NIMRMbeya RT @TBtrials_StAnd: “We MUST run faster than the diseases through prevention & management factoring multidisciplinary approaches collaborat…
NIMRMbeya Deputy Minister MoHCDGEC Dr. Faustine Ndugulile (sitted at the center) in a group photo with members of the Execu… https://t.co/g6GVYT9mu3
NIMRMbeya Deputy Minister MoHCDGEC Dr. Faustine Ndugulile giving a commencement speech for the annual PanACEA Consortium mee… https://t.co/p3XGG56KBd
NIMRMbeya RT @PanACEA_II: The 10th PanACEA Annual Meeting in Mbeya, TZ is officially opened by centre director Dr Ntingya, council chair Dr Mtasiwa,…
© 2017 NIMR - Mbeya Medical Research Center